Blue Water Vaccines, a Cincinnati, OH-based company developing a universal flu vaccine based on technology developed at the University of Oxford, raised $7m in seed funding.
The round was led by CincyTech, with participation from CincyTech-affiliated private investors.
The financing follows a preclinical study which offered early validation of the company’s novel approach to vaccine design.
The capital will now finance an additional preclinical study, followed by a Phase 1 trial targeted for 2020.
Led by Joseph Hernandez, CEO, Blue Water Vaccines uses technology developed by scientists at the University of Oxford to develop a single vaccine that protects against all influenza strains.
The company secured exclusive rights to the vaccine from Oxford University Innovation, the research commercialisation company of the University of Oxford, UK.